Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States.

ABSTRACT:

Importance

Clinical data on hepatitis C virus (HCV) treatment rates in the United States are sparse.

Objective

To evaluate HCV treatment rates in the era of direct-acting antivirals (DAAs).

Design, setting, and participants

This retrospective cohort study used data from the deidentified Optum Cliniformatics Data Mart Database (2014-2021) on patients with HCV in the DAA and COVID-19 eras. The database includes patients with private health insurance in the US.

Main outcomes and measures

The treatment rate and changes over time were assessed with adjusted log-binomial regression, and factors associated with treatment were examined using multivariable logistic regression.

Results

A total of 133 348 patients with HCV (79 567 [59.7%] men; mean [SD] age, 59.7 [

SUBMITTER: Nguyen VH 

PROVIDER: S-EPMC9856330 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature